Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Medical Specialties (23)
- Medical Sciences (21)
- Oncology (20)
- Life Sciences (19)
- Bioinformatics (9)
-
- Biomedical Informatics (9)
- Chemicals and Drugs (7)
- Analytical, Diagnostic and Therapeutic Techniques and Equipment (6)
- Cell and Developmental Biology (6)
- Cancer Biology (5)
- Genetic Phenomena (5)
- Medical Genetics (5)
- Amino Acids, Peptides, and Proteins (4)
- Biological Phenomena, Cell Phenomena, and Immunity (4)
- Therapeutics (4)
- Immunology and Infectious Disease (3)
- Immunotherapy (3)
- Medical Molecular Biology (3)
- Translational Medical Research (3)
- Biological Factors (2)
- Biology (2)
- Cell Biology (2)
- Cellular and Molecular Physiology (2)
- Chemical Actions and Uses (2)
- Diagnosis (2)
- Digestive System Diseases (2)
- Medical Cell Biology (2)
- Institution
- Publication
-
- Faculty, Staff and Student Publications (9)
- Faculty, Staff and Students Publications (4)
- School of Medicine Faculty Publications (4)
- Dissertations and Theses (Open Access) (3)
- Kimmel Cancer Center Faculty Papers (3)
-
- Department of Pharmacology, Physiology, and Cancer Biology Faculty Papers (2)
- School of Graduate Studies Faculty Publications (2)
- Department of Medical Oncology Faculty Papers (1)
- Department of Otolaryngology - Head and Neck Surgery Faculty Papers (1)
- Department of Pathology, Anatomy, and Cell Biology Faculty Papers (1)
- Journal Articles: Eppley Institute (1)
- Rowan-Virtua Research Day (1)
- Theses and Dissertations (ETD) (1)
- Publication Type
Articles 31 - 33 of 33
Full-Text Articles in Neoplasms
Phosphoinositide 3-Kinase Signaling Pathway In Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, And Therapeutics, Divya Murthy, Kuldeep S. Attri, Pankaj K. Singh
Phosphoinositide 3-Kinase Signaling Pathway In Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, And Therapeutics, Divya Murthy, Kuldeep S. Attri, Pankaj K. Singh
Journal Articles: Eppley Institute
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized by its sudden manifestation, rapid progression, poor prognosis, and limited therapeutic options. Genetic alterations in key signaling pathways found in early pancreatic lesions are pivotal for the development and progression of pancreatic intraepithelial neoplastic lesions into invasive carcinomas. More than 90% of PDAC tumors harbor driver mutations in K-Ras that activate various downstream effector-signaling pathways, including the phosphoinositide-3-kinase (PI3K) pathway. The PI3K pathway also responds to stimuli from various growth factor receptors present on the cancer cell surface that, in turn, modulate downstream signaling cascades. Thus, the inositide signaling acts …
Microenvironment-Induced Pten Loss By Exosomal Microrna Primes Brain Metastasis Outgrowth, Lin Zhang
Microenvironment-Induced Pten Loss By Exosomal Microrna Primes Brain Metastasis Outgrowth, Lin Zhang
Dissertations and Theses (Open Access)
Development of life-threatening cancer metastases at distant organs requires disseminated tumor cells’ adaptation to and co-evolution with the drastically different microenvironments of metastatic sites. Cancer cells of common origin manifest distinct gene expression patterns after metastasizing to different organs. Clearly, the dynamic interplay between metastatic tumor cells and extrinsic signals at individual metastatic organ sites critically impacts the subsequent metastatic outgrowth. Yet, it is unclear when and how disseminated tumor cells acquire the essential traits from the microenvironment of metastatic organs that prime their subsequent outgrowth. Here we show that primary tumor cells with normal expression of PTEN, an important …
Role Of The Ang-Tie2 Pathway In The Invasive Recurrence Of Gbm Following Anti-Vegf Therapy, Nahir Cortes Santiago
Role Of The Ang-Tie2 Pathway In The Invasive Recurrence Of Gbm Following Anti-Vegf Therapy, Nahir Cortes Santiago
Dissertations and Theses (Open Access)
Strong pre-clinical and clinical data supporting the effectiveness of bevacizumab, a humanized monoclonal anti-VEGF antibody, for the treatment of gliomas led to its accelerated approval for the treatment of patients with recurrent glioma. However, despite strong anti-tumor effects, upon treatment with bevacizumab, patients will invariably recur with a tumor characterized by enhanced invasiveness and resistance to therapy. This study aims to elucidate the mechanisms leading to this enhanced malignancy with the hope of uncovering new potential therapeutic targets for combined treatment. Using tissue sections from U87-derived glioma bearing mice treated with or without aflibercept (another anti-VEGF antibody) we have gathered …